Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
This study determined the maximum tolerated dose and safety of SU011248 (sunitinib malate,
SUTENT) in combination with FOLFOX [Leucovorin + Fluorouracil (5-FU) + Oxaliplatin]. Three
different dosing regimens with starting doses of sunitinib at 37.5 mg/day (Schedule 2/2,
Schedule 4/2, and Continuous Dosing) were tested in patients with advanced solid tumors,
including colorectal cancer.